Core One’s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
VANCOUVER, BC / ACCESSWIRE / July 28, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), is excited to share positive...